Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

PURPOSE: Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and tem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: DuBois, Steven G., Marachelian, Araz, Fox, Elizabeth, Kudgus, Rachel A., Reid, Joel M., Groshen, Susan, Malvar, Jemily, Bagatell, Rochelle, Wagner, Lars, Maris, John M., Hawkins, Randall, Courtier, Jesse, Lai, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Matthay, Katherine K., Mosse, Yael P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872349/
https://ncbi.nlm.nih.gov/pubmed/26884555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.4889
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados